Nivolumab in Previously Untreated Melanoma withoutBRAFMutation
Top Cited Papers
- 22 January 2015
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 372 (4), 320-330
- https://doi.org/10.1056/nejmoa1412082
Abstract
Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study.Keywords
This publication has 18 references indexed in Scilit:
- Use of Statins and the Risk of Death in Patients With Prostate CancerJournal of Clinical Oncology, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2013
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaThe New England Journal of Medicine, 2012
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibThe New England Journal of Medicine, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009